The PE Ratio as of September 2024 (TTM) for Molecular Partners AG (MOLN) is -2.67

According to Molecular Partners AG’s latest financial reports and current stock price. The company's current PE Ratio is -2.67. This represents a change of 2.95% compared to the average of -2.59 of the last 4 quarters.

Molecular Partners AG (MOLN) Historical PE Ratio (quarterly & annually)

How has MOLN PE Ratio performed in the past?

The mean historical PE Ratio of Molecular Partners AG over the last ten years is -278.43. The current -2.67 PE Ratio has changed -4.11% with respect to the historical average. Over the past ten years (40 quarters), MOLN's PE Ratio was at its highest in in the December 2015 quarter at 82.46. The PE Ratio was at its lowest in in the March 2015 quarter at -36.73.

Molecular Partners AG (MOLN) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Molecular Partners AG PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Molecular Partners AG (MOLN) Average PE Ratio

How has MOLN PE Ratio performed in the past?

The current PE Ratio of Molecular Partners AG (MOLN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Molecular Partners AG (MOLN) PE Ratio vs. Peers

How is MOLN’s PE Ratio compared to its peers?

Molecular Partners AG’s PE Ratio is greater than Mineralys Therapeutics, Inc. (-4.63), less than AN2 Therapeutics, Inc. (-0.47), greater than Pharvaris N.V. (-8.20), greater than PepGen Inc. (-3.22), greater than MediciNova, Inc. (-12.61), greater than Anebulo Pharmaceuticals, Inc. (-4.99), greater than Champions Oncology, Inc. (-7.94), greater than Cyteir Therapeutics, Inc. (-3.52), greater than Rezolute, Inc. (-3.80), less than HCW Biologics Inc. (-0.69), greater than Eliem Therapeutics, Inc. (-3.49), less than PMV Pharmaceuticals, Inc. (-1.58), greater than Edgewise Therapeutics, Inc. (-14.14), less than Rallybio Corporation (-0.66), less than Opthea Limited (-1.11), greater than Monte Rosa Therapeutics, Inc. (-3.11), less than Entrada Therapeutics, Inc. (4.84), less than Vigil Neuroscience, Inc. (-1.65),

Build a custom stock screener for Molecular Partners AG (MOLN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Molecular Partners AG using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Molecular Partners AG (MOLN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Molecular Partners AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.